Research Topics
Species | P MarksSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cellsP A Marks
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Natl Cancer Inst 92:1210-6. 2000..The hydroxamic acid-based HPCs are potentially effective agents for cancer therapy and, possibly, cancer chemoprevention...- Histone deacetylase inhibitors as new cancer drugsP A Marks
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Curr Opin Oncol 13:477-83. 2001..Several structurally different histone deacetylase inhibitors are in phase I or II clinical trials in patients with cancers... - Histone deacetylases and cancer: causes and therapiesP Marks
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Nat Rev Cancer 1:194-202. 2001..HDAC inhibitors are proving to be an exciting therapeutic approach to cancer, but how do they exert this effect?.. - The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)Paul A Marks
Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
Cell Cycle 3:534-5. 2004..Gui et al. have identified effects of SAHA on p21(WAF1) promotor associated proteins that explain, at least in part, the selective effects of HDAC in altering gene expression... - Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acidWilliam Kevin Kelly
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Nat Clin Pract Oncol 2:150-7. 2005..SAHA is one of the HDAC inhibitors most advanced in development. It is in phase I and II clinical trials for patients with both hematologic and solid tumors... - Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effectsWei-Sheng Xu
Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 65:7832-9. 2005..The present findings indicate that the HDAC inhibitor could exert antitumor effects by inducing polyploidy, and this effect is more marked in transformed cells with nonfunctioning p21WAF1 or p53 genes... - Prospects: histone deacetylase inhibitorsMilos Dokmanovic
Memorial Sloan-Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research New York City, New York 10021, USA
J Cell Biochem 96:293-304. 2005..The answers to these questions will have therapeutic importance since we will identify targets for enhancing the efficacy and safety of HDACi... - Novel histone deacetylase inhibitors in the treatment of thyroid cancerConstantine S Mitsiades
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Clin Cancer Res 11:3958-65. 2005..g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available... 
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancerWilliam Kevin Kelly
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Oncol 23:3923-31. 2005..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...- Histone deacetylase inhibitors: discovery and development as anticancer agentsPaul A Marks
Memorial Sloan Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research, New York City, New York 10021, USA
Expert Opin Investig Drugs 14:1497-511. 2005..HDAC inhibitors can induce cancer cell death, whereas normal cells are relatively resistant to HDAC inhibitor-induced cell death... - Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitorWeisheng Xu
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 103:15540-5. 2006..Identifying these differences can have predictive value in assessing therapeutic response and identifying targets to enhance therapeutic efficacy... - A man who has made his Marks on scienceKaren Honey
J Clin Invest 116:2833. 2006 - Thioredoxin in cancer--role of histone deacetylase inhibitorsPaul A Marks
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Semin Cancer Biol 16:436-43. 2006..Up-regulation of TBP-2 and decrease of Trx may contribute to the sensitivity of many hematologic and solid tumors to anti-cancer activity of HDACi... - Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugPaul A Marks
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Nat Biotechnol 25:84-90. 2007..A new drug application was approved by the US Food and Drug Administration for vorinostat for treatment of cutaneous T-cell lymphoma. More potent analogs of SAHA have shown unacceptable toxicity... - Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferationDeborah L Marrocco
Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia
Mol Cancer Ther 6:51-60. 2007..Consequently, combinatorial treatments that target different components of the AR pathway may afford a more effective strategy to control the growth of prostate cancer cells... - Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphomaR K Lindemann
Cancer Immunology Program, The Peter MacCallum Cancer Institute, Trescowthick Research Laboratories, St Andrews Place, East Melbourne, Victoria 3002, Australia
Proc Natl Acad Sci U S A 104:8071-6. 2007..Our studies provide important information regarding the mechanisms of action of HDACi that have broad implications regarding stratification of patients receiving HDACi therapy alone or in combination with other anticancer agents... - Histone deacetylase inhibitors selectively suppress expression of HDAC7Milos Dokmanovic
Cell Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Mol Cancer Ther 6:2525-34. 2007..Selective down-regulation of HDAC7 protein may serve as a marker of response of tumors to HDACi... - Histone deacetylase inhibitors: overview and perspectivesMilos Dokmanovic
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Mol Cancer Res 5:981-9. 2007..A hypothesis is presented to explain the relative resistance of normal cells to HDACi-induced cell death... - Histone deacetylase inhibitors in programmed cell death and cancer therapyPaul A Marks
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cell Cycle 4:549-51. 2005..In this review, we discuss the study of HDAC inhibitors in cell death and cancer research, the implications of our recent findings, and some outstanding questions that need to be addressed... - Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitorsMelissa J Peart
The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia
Proc Natl Acad Sci U S A 102:3697-702. 2005.... - Apoptotic and autophagic cell death induced by histone deacetylase inhibitorsYufang Shao
Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Proc Natl Acad Sci U S A 101:18030-5. 2004..Induction of autophagic cell death by HDAC inhibitors has clear clinical implications in treating cancers with apoptotic defects... - Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumorsLeonard A Cohen
Div Nutrition and Endocrinology, American Health Foundation, Valhalla, NY 10595, USA
Anticancer Res 22:1497-504. 2002..The results of this animal model study indicate that SAHA, when fed in the diet, serves as both a chemopreventive and chemotherapeutic agent in the absence of any detectable side effects... - The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 99:11700-5. 2002.... - Histone deacetylase inhibitors: from target to clinical trialsWilliam K Kelly
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Expert Opin Investig Drugs 11:1695-713. 2002..Several HDAC inhibitors are currently in clinical trials as anticancer agents and, in particular, hydroxamic acid-based HDAC inhibitors have shown activity against cancers at well-tolerated doses... - Molecular sequelae of histone deacetylase inhibition in human malignant B cellsNicholas Mitsiades
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Blood 101:4055-62. 2003.... - Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's diseaseEmma Hockly
Medical and Molecular Genetics, Guy's, King's and St. Thomas' School of Medicine, King's College London, Eighth Floor Guy's Tower, Guy's Hospital, London SE1 9RT, United Kingdom
Proc Natl Acad Sci U S A 100:2041-6. 2003..SAHA dramatically improved the motor impairment in R6/2 mice, clearly validating the pursuit of this class of compounds as HD therapeutics... - Histone deacetylasesPaul A Marks
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Curr Opin Pharmacol 3:344-51. 2003..Results of clinical trials with several of these agents have indicated that they are well tolerated at doses that have anti-tumour activity... - Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenouslyWm Kevin Kelly
Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 9:3578-88. 2003..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer... - Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitroMartha C Kutko
Department of Pediatric Surgery, Sloan Kettering Institute and Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 9:5749-55. 2003..CONCLUSIONS: SAHA and pyroxamide induce growth suppression and cell death in human RMS in vitro. Accumulation of acetylated histones and induction of p21/WAF1 expression are observed in cells exposed to either agent... - Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivoVictoria M Richon
Discovery Biology, Aton Pharma, Inc, Tarrytown, New York 10591, USA
Methods Enzymol 376:199-205. 2004 - Histone deacetylase inhibitorsPaul A Marks
Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Adv Cancer Res 91:137-68. 2004..2001; Kelly et al., 2002a,b; Piekarz et al., 2001; Wozniak et al., 1999)... - The American Society for Clinical Investigation--the first 100 yearsPaul A Marks
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
J Clin Invest 118:1223-4. 2008.... - Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implicationsConstantine S Mitsiades
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 101:540-5. 2004..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM... - Histone deacetylase inhibitors: development as cancer therapyPaul A Marks
Cell Biology Program, Sloan Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, USA
Novartis Found Symp 259:269-81; discussion 281-8. 2004.... - Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acidChristopher M Reilly
Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University and Edward Via College of Osteopathic Medicine, Blacksburg, 24060, USA
J Immunol 173:4171-8. 2004..These data indicate that SAHA blocks mesangial cell inflammatory mediator production in vitro and disease progression in vivo in MRL/lpr mice... - Blasts from the pastPaul A Insel
J Clin Invest 114:1017-33. 2004....